Universitätsklinikum Köln

EARLY CHILDHOOD HEIGHT-ADJUSTED TOTAL KIDNEY VOLUME AS A RISK MARKER OF KIDNEY SURVIVAL IN AUTOSOMAL RECESSIVE POLYCYSTIC KIDNEY DISEASE (ARPKD) (2021) Burgmaier K, Kilian S, Arbeiter K, Atmis B, Buescher A, Derichs U, Dursun I, et al. Conference contribution PHENOCOPIESOF CLINICALLY DIAGNOSED ARPKD REVEALED IN CHILDREN (2021) Halawi A, Burgmaier K, Buescher A, Dursun I, Galiano M, Gessner M, Gokce I, et al. Conference contribution Innovative radiation oncology Together - Precise, Personalized, Human Vision 2030 for radiotherapy & radiation oncology in Germany (2021) Krug D, Hecht M, Ebert N, Maeurer M, Fleischmann DF, Fokas E, Straube C, et al. Journal article MSI testing What's new? What should be considered? (2021) Rueschoff J, Baretton G, Blaeker H, Dietmaier W, Dietel M, Hartmann A, Horn LC, et al. Journal article, Review article Value of PET imaging for radiation therapy (2021) Lapa C, Nestle U, Albert NL, Baues C, Beer A, Buck A, Budach V, et al. Journal article, Review article Effective connectivity in the default mode network is distinctively disrupted in Alzheimer's disease—A simultaneous resting-state FDG-PET/fMRI study (2021) Scherr M, Utz L, Tahmasian M, Pasquini L, Grothe MJ, Rauschecker JP, Grimmer T, et al. Journal article Response to treatment of uncommon EGFR mutations - a retrospective analysis from the German National Network Genomic Medicine Lung Cancer (nNGM) (2021) Janning M, Sueptitz J, Forstreuter A, Albers-Leischner C, Tufman A, Velthaus-Rusik JL, Reck M, et al. Conference contribution Patient-reported treatment satisfaction with Rivaroxaban in cancer patients with acute venous thromboembolism - Results from the CONKO-011 trial (2021) Sinn M, Juehling A, Hellmann M, Omar M, Suedhoff T, Stahl M, Krziwanie A, et al. Conference contribution Control of PD-L1 expression in CLL-cells by stromal triggering of the Notch-c-Myc-EZH2 oncogenic signaling axis (2021) Böttcher M, Bruns H, Lu J, Chartomatsidou E, Papakonstantinou N, Mentz K, Büttner-Herold M, et al. Conference contribution Abatacept Reverses Subclinical Arthritis in Patients with High-risk to Develop Rheumatoid Arthritis -results from the Randomized, Placebo-controlled ARIAA Study in RA-at Risk Patients (2021) Rech J, Hueber A, Ostergaard M, Tascilar K, Hagen M, Mendez LV, Kleyer A, et al. Conference contribution